Next Article in Journal
HIV-1 Tat: Its Dependence on Host Factors is Crystal Clear
Next Article in Special Issue
Therapeutic Vaccines and Antibodies for Treatment of Orthopoxvirus Infections
Previous Article in Journal
Serotype Chimeric Human Adenoviruses for Cancer GeneTherapy
Previous Article in Special Issue
Use of the Aerosol Rabbitpox Virus Model for Evaluation of Anti-Poxvirus Agents
Viruses 2010, 2(10), 2213-2225; doi:10.3390/v2102213
Review

Synthesis and Early Development of Hexadecyloxypropyl-cidofovir: An Oral Antipoxvirus Nucleoside Phosphonate

1,2
Received: 26 August 2010; in revised form: 8 September 2010 / Accepted: 8 September 2010 / Published: 30 September 2010
(This article belongs to the Special Issue Antivirals Against Poxviruses)
Download PDF [135 KB, uploaded 30 September 2010]
Abstract: Hexadecyloxypropyl-cidofovir (HDP-CDV) is a novel ether lipid conjugate of (S)-1-(3-hydroxy-2-phosphonoylmethoxypropyl)-cytosine (CDV) which exhibits a remarkable increase in antiviral activity against orthopoxviruses compared with CDV. In contrast to CDV, HDP-CDV is orally active and lacks the nephrotoxicity of CDV itself. Increased oral bioavailability and increased cellular uptake is facilitated by the lipid portion of the molecule which is responsible for the improved activity profile. The lipid portion of HDP-CDV is cleaved in the cell, releasing CDV which is converted to CDV diphosphate, the active metabolite. HDP-CDV is a highly effective agent against a variety of orthopoxvirus infections in animal models of disease including vaccinia, cowpox, rabbitpox and ectromelia. Its activity was recently demonstrated in a case of human disseminated vaccinia infection after it was added to a multiple drug regimen. In addition to the activity against orthopoxviruses, HDP-CDV (CMX001) is active against all double stranded DNA viruses including CMV, HSV-1, HSV-2, EBV, adenovirus, BK virus, orf, JC, and papilloma viruses, and is under clinical evaluation as a treatment for human infections with these agents.
Keywords: antiviral drugs; Cidofovir; HPMPA; acyclic nucleoside phosphonates; smallpox; vaccinia; biodefense antiviral drugs; Cidofovir; HPMPA; acyclic nucleoside phosphonates; smallpox; vaccinia; biodefense
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Hostetler, K.Y. Synthesis and Early Development of Hexadecyloxypropyl-cidofovir: An Oral Antipoxvirus Nucleoside Phosphonate. Viruses 2010, 2, 2213-2225.

AMA Style

Hostetler KY. Synthesis and Early Development of Hexadecyloxypropyl-cidofovir: An Oral Antipoxvirus Nucleoside Phosphonate. Viruses. 2010; 2(10):2213-2225.

Chicago/Turabian Style

Hostetler, Karl Y. 2010. "Synthesis and Early Development of Hexadecyloxypropyl-cidofovir: An Oral Antipoxvirus Nucleoside Phosphonate." Viruses 2, no. 10: 2213-2225.


Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert